Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 15/20 | 0.75 |
| ▸ | SLC6A9 | P48067 | 15/20 | 0.75 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | IDE | P14735 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3925750 | 0.97 | SLC6A5 (0.79) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL3923023 | 0.91 | TDP1 (0.68) | SLC6A5SLC6A9PAX8SMN1; SMN2 | |
| SCHEMBL5046650 | 0.87 | SLC6A9 (0.80) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL3921080 | 0.87 | SLC6A9 (0.79) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL3919355 | 0.86 | SLC6A5 (1.00) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL3920692 | 0.86 | PAX8 (1.00) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL13687926 | 0.85 | SLC6A9 (0.76) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL3919360 | 0.85 | SLC6A9 (0.80) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL13687887 | 0.84 | IDE (0.88) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE | |
| SCHEMBL3917370 | 0.83 | SLC6A9 (1.00) | SLC6A5SLC6A9PAX8SMN1; SMN2IDE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427612-B2 | Benzoyl-piperazine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1663232-B1 | 1-(2-AMINO-BENZOYL)-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES | HOFFMANN LA ROCHE (CH) | 2007-10-03 | — | — | EP | disclosed |